Investigation of altered urinary metabolomic profiles of invasive ductal carcinoma of breast using targeted and untargeted approaches
Invasive ductal carcinoma (IDC) is a type of breast cancer, usually detected in advanced stages due to its asymptomatic nature which ultimately leads to low survival rate. Identification of urinary metabolic adaptations induced by IDC to understand the disease pathophysiology and monitor therapy response would be a helpful approach in clinical settings. Moreover, its non-invasive and cost effective strategy better suited to minimize apprehension among high risk population.
This study aims toward investigating the urinary metabolic alterations of IDC by targeted (LC-MRM/MS) and untargeted (GC–MS) approaches for the better understanding of the disease pathophysiology and monitoring therapy response.
Urinary metabolic alterations of IDC subjects (63) and control subjects (63) were explored by targeted (LC-MRM/MS) and untargeted (GC–MS) approaches. IDC specific urinary metabolomics signature was extracted by applying both univariate and multivariate statistical tools.
Statistical analysis identified 39 urinary metabolites with the highest contribution to metabolomic alterations specific to IDC. Out of which, 19 metabolites were identified from targeted LC-MRM/MS analysis, while 20 were identified from the untargeted GC–MS analysis. Receiver operator characteristic (ROC) curve analysis evidenced 6 most discriminatory metabolites from each type of approach that could differentiate between IDC subjects and controls with higher sensitivity and specificity. Furthermore, metabolic pathway analysis depicted several dysregulated pathways in IDC including sugar, amino acid, nucleotide metabolism, TCA cycle etc.
Overall, this study provides valuable inputs regarding altered urinary metabolites which improved our knowledge on urinary metabolomic alterations induced by IDC. Moreover, this study identified several dysregulated metabolic pathways which offer further insight into the disease pathophysiology.
KeywordsBreast cancer Invasive ductal carcinoma Urine Metabolomics LC-MRM/MS GC–MS
The authors are grateful to all the volunteers who participated in this study. THM acknowledges Department of Biotechnology, Govt. of India for fellowship. RT acknowledges Council of Scientific and Industrial Research, New Delhi, India for research associateship.
Conceived the study: THM, RT, SR; Designed the study: THM, RT, SR; Performed the experiments: THM, RT; Compiled the data: THM, RT, KT, VC, VN, SR; Analyzed the data and performed the multivariate statistical analysis and bioinformatics: THM, RT, KT, VC, VN, SR; Drafted the manuscript: THM, AM, SR; Provided clinical samples: AM; Provided chemicals and reagents: SR.
This research was supported by Department of Biotechnology, Govt. of India, India (RGYI Grant No. BT/PR6384/GBD/27/409/2012).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interests in relation to the work described.
The study was approved by the Ethics Committee of the Poona medical research foundation and National Centre for Cell Science (NCCS), Pune.
Fasting urine samples were collected with institutional review approval and after informed consent from all individual participants included in the study.
Research involving human participants and/or animals
All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- Christensen, B. C., Smith, A. A., Zheng, S., Koestler, D. C., Houseman, E. A., Marsit, C. J., et al. (2011). DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. The Journal of the National Cancer Institute, 103(2), 143–153. https://doi.org/10.1093/jnci/djq497.CrossRefPubMedGoogle Scholar
- DeSantis, C. E., Fedewa, S. A., Goding Sauer, A., Kramer, J. L., Smith, R. A., & Jemal, A. (2016). Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA: A Cancer Journal for Clinicians, 66(1), 31–42. https://doi.org/10.3322/caac.21320.CrossRefGoogle Scholar
- Eriksson, L., Byrne, T., Johansson, E., Trygg, J., & Vikström, C. (2013). Multi-and megavariate data analysis basic principles and applications: Umetrics Academy.Google Scholar
- Fan, Y., Zhou, X., Xia, T. S., Chen, Z., Li, J., Liu, Q., et al. (2016). Human plasma metabolomics for identifying differential metabolites and predicting molecular subtypes of breast cancer. Oncotarget, 7(9), 9925–9938. https://doi.org/10.18632/oncotarget.7155.CrossRefPubMedPubMedCentralGoogle Scholar
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136(5), E359–E386. https://doi.org/10.1002/ijc.29210.CrossRefPubMedGoogle Scholar
- Fernandez-Peralbo, M. A., Gomez-Gomez, E., Calderon-Santiago, M., Carrasco-Valiente, J., Ruiz-Garcia, J., Requena-Tapia, M. J., et al. (2016). Prostate cancer patients-negative biopsy controls discrimination by untargeted metabolomics analysis of urine by LC-QTOF: Upstream information on other omics. Scientific Reports, 6, 38243. https://doi.org/10.1038/srep38243.CrossRefPubMedPubMedCentralGoogle Scholar
- Ferretti, A., D’Ascenzo, S., Knijn, A., Iorio, E., Dolo, V., Pavan, A., et al. (2002). Detection of polyol accumulation in a new ovarian carcinoma cell line, CABA I: a(1)H NMR study. British Journal of Cancer, 86(7), 1180–1187. https://doi.org/10.1038/sj.bjc.6600189.CrossRefPubMedPubMedCentralGoogle Scholar
- Griffin, J. L., Nicholls, A. W., Daykin, C. A., Heald, S., Keun, H. C., Schuppe-Koistinen, I., et al. (2007). Standard reporting requirements for biological samples in metabolomics experiments: Mammalian/in vivo experiments. Metabolomics, 3(3), 179–188. https://doi.org/10.1007/s11306-007-0077-z.CrossRefGoogle Scholar
- Hart, C. D., Tenori, L., Luchinat, C., & Di Leo, A. (2016). Metabolomics in breast cancer: Current status and perspectives. In Novel biomarkers in the continuum of breast cancer (pp. 217–234): Springer.Google Scholar
- Jerzak, K. J., Laureano, M., Elsharawi, R., Kavsak, P., Chan, K. K., Dhesy-Thind, S. K., et al. (2017). Targeted metabolomics in colorectal cancer: A strategic approach using standardized laboratory tests of the blood and urine. Hypoxia, 5, 61–66. https://doi.org/10.2147/HP.S127560.CrossRefPubMedPubMedCentralGoogle Scholar
- Kelly, R. S., Heiden, M. G., Giovannucci, E., & Mucci, L. A. (2016). Metabolomic biomarkers of prostate cancer: Prediction, diagnosis, progression, prognosis, and recurrence. Cancer Epidemiology and Prevention Biomarkers, 137, 2124–2132.Google Scholar
- Li, M. (2015). Urine reflection of changes in blood. In Urine proteomics in kidney disease biomarker discovery (pp. 13–19): Springer.Google Scholar
- Makowski, L., Zhou, C., Zhong, Y., Kuan, P. F., Fan, C., Sampey, B. P., et al. (2014). Obesity increases tumor aggressiveness in a genetically engineered mouse model of serous ovarian cancer. Gynecologic Oncology, 133(1), 90–97. https://doi.org/10.1016/j.ygyno.2013.12.026.CrossRefPubMedPubMedCentralGoogle Scholar
- Sharma, G. N., Dave, R., Sanadya, J., Sharma, P., & Sharma, K. K. (2010). Various types and management of breast cancer: An overview. Journal of Advanced Pharmaceutical Technology & Research, 1(2), 109–126.Google Scholar
- Yeganeh, B., Wiechec, E., Ande, S. R., Sharma, P., Moghadam, A. R., Post, M., et al. (2014). Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacology & Therapeutics, 143(1), 87–110. https://doi.org/10.1016/j.pharmthera.2014.02.007.CrossRefGoogle Scholar